Gilles Freyer

Patients’ and oncologists’ perspectives on shared decision-making and treatment communication in HR+/HER2 − advanced breast cancer: a multicountry survey

Hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) represents approximately 70% of all cases. In locally advanced or metastatic stages (laBC/mBC), patients’ quality of life (QoL) often worsens, making shared decision-maki...